News for Transcept Pharmaceuticals Inc - Google Finance

Drug Delivery Partnering Terms and Agreements

Thu, 13 Jun 2013 17:11:58 GMT

Drug Delivery Partnering Terms and Agreements
Sacramento Bee - Jun 13, 2013

Big pharma drug delivery partnering company profiles Abbott Actavis Inc (formerly Watson Pharmaceuticals) Actavis (merged with Watson Pharmaceuticals Oct 2012) Actelion Allergan Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec ... Tel ...

TOP GAINERS Pre Market Today – Novavax Inc, FuelCell Energy, Clovis ...

Thu, 06 Jun 2013 14:05:48 GMT

TOP GAINERS Pre Market Today – Novavax Inc, FuelCell Energy, Clovis ...
Pentagon Post - Jun 6, 2013

Price-to-earnings ratio is 26.65. Market capitalization: $173.46 million. Transcept Pharmaceuticals Incorporated (NASDAQ: TSPT) currently trades at $3.17, up 5.1 percent in Pre-Market with 15,020 share volume.

Transcept Pharmaceuticals Inc Announces Phase Two Clinical Trial Of TO-2061 As Adjunctive Therapy For Obsessive Compulsive Disorder Did Not Meet Primary Endpoint

Fri, 21 Dec 2012 12:30:08 GMT

Transcept Pharmaceuticals Inc Announces Phase Two Clinical Trial Of TO-2061 As Adjunctive Therapy For Obsessive Compulsive Disorder Did Not Meet Primary Endpoint
Reuters Key Development - Dec 21, 2012

Transcept Pharmaceuticals, Inc. Appoints Leone Patterson As Vice President And Chief Financial Officer

Tue, 26 Jun 2012 20:02:00 GMT

Transcept Pharmaceuticals, Inc. Appoints Leone Patterson As Vice President And Chief Financial Officer
Reuters Key Development - Jun 26, 2012

Transcept Pharmaceuticals, Inc. Prices Public Offering Of Common Stock

Thu, 26 Apr 2012 12:03:00 GMT

Transcept Pharmaceuticals, Inc. Prices Public Offering Of Common Stock
Reuters Key Development - Apr 26, 2012

Transcept Pharmaceuticals, Inc. Announces Proposed Public Offering

Wed, 25 Apr 2012 20:03:00 GMT

Transcept Pharmaceuticals, Inc. Announces Proposed Public Offering
Reuters Key Development - Apr 25, 2012

Transcept Pharmaceuticals, Inc. Announces FDA Approval Of Intermezzo C-IV

Wed, 23 Nov 2011 18:54:46 GMT

Transcept Pharmaceuticals, Inc. Announces FDA Approval Of Intermezzo C-IV
Reuters Key Development - Nov 23, 2011

Transcept Pharmaceuticals, Inc. Announces Plan to Resubmit Intermezzo New Drug Application Following Meeting With U.S. Food & Drug Administration

Wed, 14 Sep 2011 20:05:00 GMT

Transcept Pharmaceuticals, Inc. Announces Plan to Resubmit Intermezzo New Drug Application Following Meeting With U.S. Food & Drug Administration
Reuters Key Development - Sep 14, 2011

Transcept Pharmaceuticals, Inc. Announces FDA Response to Proposal in Support of Intermezzo New Drug Application

Wed, 14 Sep 2011 02:23:00 GMT

Transcept Pharmaceuticals, Inc. Announces FDA Response to Proposal in Support of Intermezzo New Drug Application
Reuters Key Development - Sep 14, 2011

Transcept Pharmaceuticals, Inc. Announces Plans to Reduce Expenses by Decreasing Staff Following Complete Response Letter from FDA on Intermezzo New Drug Application; Sees Charges In Q3 2011

Sat, 16 Jul 2011 00:02:00 GMT

Transcept Pharmaceuticals, Inc. Announces Plans to Reduce Expenses by Decreasing Staff Following Complete Response Letter from FDA on Intermezzo New Drug Application; Sees Charges In Q3 2011
Reuters Key Development - Jul 16, 2011